The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) announced that “the U.S. government is conducting a comprehensive assessment of the U.S. Active Pharmaceutical Ingredient (API) industrial base to gain an understanding of the supply chain network that underpins U.S. pharmaceutical manufacturing capabilities.” BIS's website has the release.
With this information, the federal government will be able to “more accurately plan and develop funding strategies to help ensure the availability and security of the API supply chain and to raise awareness of current limited domestic manufacturing capabilities, among other potential issues.”
BIS will survey “hundreds of U.S. API manufacturers, distributors, suppliers, and customers” in support of this goal. The effort will “identify interdependencies between respondents, suppliers, customers, and U.S. government agencies while also benchmarking performance across multiple tiers of the API industry.”
The assessment was requested by “HHS’s Administration for Strategic Preparedness and Response (ASPR) to support its mission to build a diverse, agile public health supply chain and sustain long-term U.S. manufacturing capabilities.”
